Article
The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms.
Clinical pharmacology and therapeutics - 1 May 2022
Cooper-DeHoff Rhonda M, Niemi Mikko, Ramsey Laura B, Luzum Jasmine A, Tarkiainen E Katriina, Straka Robert J, Gong Li, Tuteja Sony, Wilke Russell A, Wadelius Mia, Larson Eric A, Roden Dan M, Klein Teri E, Yee Sook Wah, Krauss Ronald M, Turner Richard M, Palaniappan Latha, Gaedigk Andrea, Giacomini Kathleen M, Caudle Kelly E, Voora Deepak
Abstract excerpt
Statins reduce cholesterol, prevent cardiovascular disease, and are among the most commonly prescribed medications in the world. Statin-associated musculoskeletal symptoms (SAMS) impact statin adherence and ultimately can impede the long-term effectiveness of statin therapy. There are several identified pharmacogenetic variants that impact statin disposition and adverse events during statin therapy. SLCO1B1...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.